US5800820A
(en)
*
|
1989-01-10 |
1998-09-01 |
Repligen Corporation |
Methods and compositions for treatment of angiogenic diseases
|
US5086164A
(en)
*
|
1989-01-10 |
1992-02-04 |
Repligen Corporation |
Novel methods and compositions for treatment of angiogenic diseases
|
WO1993002192A1
(en)
*
|
1991-07-15 |
1993-02-04 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
CA2106368A1
(en)
*
|
1992-01-16 |
1993-07-17 |
Theodore E. Maione |
Methods and compositions for treatment of angiogenic disease
|
US5304542A
(en)
*
|
1992-08-28 |
1994-04-19 |
University Of Louisville Research Foundation, Inc. |
Use of platelet factor 4 to inhibit osteoblast proliferation
|
CZ195193A3
(en)
*
|
1992-09-25 |
1994-04-13 |
Lilly Co Eli |
Modified factor-4 of blood platelets, process of its preparation and pharmaceutical preparation in which it is comprised
|
EP0669988B2
(en)
*
|
1992-10-29 |
2009-07-08 |
The Australian National University |
Angiogenesis inhibitory antibodies
|
CA2157388C
(en)
*
|
1993-03-01 |
1998-12-15 |
Daniel P. Witt |
Analogs for specific oligosaccharide-protein interactions and uses thereof
|
ES2157981T3
(es)
*
|
1993-03-12 |
2001-09-01 |
Xoma Technology Ltd |
Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
|
US5733872A
(en)
*
|
1993-03-12 |
1998-03-31 |
Xoma Corporation |
Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
|
US5348942A
(en)
*
|
1993-03-12 |
1994-09-20 |
Xoma Corporation |
Therapeutic uses of bactericidal/permeability increasing protein products
|
US5652332A
(en)
*
|
1993-03-12 |
1997-07-29 |
Xoma |
Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
|
US5585095A
(en)
*
|
1993-09-14 |
1996-12-17 |
Regents Of The University Of Minnesota |
Method to enhance thrombomodulin APC generation using cationic proteins
|
AU1171795A
(en)
*
|
1993-11-05 |
1995-05-23 |
Repligen Corporation |
Novel modified pf4 compositions and methods of use
|
US5753230A
(en)
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
ATE208633T1
(de)
*
|
1994-09-16 |
2001-11-15 |
Merck Patent Gmbh |
Immunokonjugate
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US5994292A
(en)
*
|
1995-05-31 |
1999-11-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
AU721034B2
(en)
|
1996-02-15 |
2000-06-22 |
Biosense, Inc. |
Catheter based surgery
|
RU2195312C2
(ru)
|
1996-05-31 |
2002-12-27 |
Дзе Скриппс Рисерч Инститьют |
СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5-ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА
|
US6443974B1
(en)
|
1996-07-28 |
2002-09-03 |
Biosense, Inc. |
Electromagnetic cardiac biostimulation
|
US6270749B1
(en)
|
1996-12-11 |
2001-08-07 |
Pharmacyclics, Inc. |
Use of Texaphyrin in ocular diagnosis and therapy
|
AU730074B2
(en)
*
|
1996-12-11 |
2001-02-22 |
Pharmacyclics, Inc. |
Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
|
WO1998034644A1
(en)
*
|
1997-02-11 |
1998-08-13 |
Qlt Phototherapeutics, Inc. |
Compositions and articles for reducing the effects of inflammation
|
US6274614B1
(en)
|
1997-02-11 |
2001-08-14 |
Qlt Inc. |
Methods, compositions and articles for reducing or preventing the effects of inflammation
|
US20030113303A1
(en)
*
|
1998-02-05 |
2003-06-19 |
Yitzhack Schwartz |
Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
|
US20030129750A1
(en)
*
|
1998-02-05 |
2003-07-10 |
Yitzhack Schwartz |
Homing of donor cells to a target zone in tissue using active therapeutics or substances
|
ES2255155T3
(es)
|
1998-02-05 |
2006-06-16 |
Biosense Webster, Inc. |
Dispositivo para la administracion intracardiaca de farmacos.
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US20040022788A1
(en)
*
|
1998-05-19 |
2004-02-05 |
Moser Tammy L. |
Compositions and methods for promoting or inhibiting angiogenesis
|
WO2000018232A1
(en)
*
|
1998-10-01 |
2000-04-06 |
Children's Medical Center Corporation |
Method of treatment of cardiovascular injuries
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
CA2356532A1
(en)
|
1999-01-15 |
2000-07-20 |
Light Sciences Corporation |
Noninvasive vascular therapy
|
EP1149168A2
(en)
*
|
1999-02-01 |
2001-10-31 |
Beth Israel Deaconess Medical Center |
Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins
|
EP1161451A4
(en)
|
1999-02-26 |
2006-05-17 |
Human Genome Sciences Inc |
HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
|
AU3755900A
(en)
*
|
1999-03-15 |
2000-10-04 |
Chiron Corporation |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
US6943153B1
(en)
|
1999-03-15 |
2005-09-13 |
The Regents Of The University Of California |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
US7261881B1
(en)
|
1999-05-20 |
2007-08-28 |
Yale University |
Modulation of angiogenesis and wound healing
|
RU2271216C2
(ru)
|
1999-12-22 |
2006-03-10 |
Дзе Скриппс Рисерч Инститьют |
Модуляторы ангиогенеза и проницаемости сосудов
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2431054A3
(en)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
KR101155294B1
(ko)
|
2000-06-16 |
2013-03-07 |
캠브리지 안티바디 테크놀로지 리미티드 |
면역특이적으로 BLyS에 결합하는 항체
|
TWI327600B
(en)
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
ATE489395T1
(de)
|
2000-12-12 |
2010-12-15 |
Medimmune Llc |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
US6815426B2
(en)
*
|
2001-02-16 |
2004-11-09 |
E. I. Du Pont De Nemours And Company |
Angiogenesis-inhibitory tripeptides, compositions and their methods of use
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
EP2228389B1
(en)
|
2001-04-13 |
2015-07-08 |
Human Genome Sciences, Inc. |
Antibodies against vascular endothelial growth factor 2
|
US7064189B2
(en)
|
2001-05-25 |
2006-06-20 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
US20070015144A9
(en)
*
|
2001-05-25 |
2007-01-18 |
Genset, S.A. |
Human cDNAs and proteins and uses thereof
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
US7390885B2
(en)
*
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
US7365167B2
(en)
*
|
2001-11-26 |
2008-04-29 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
AU2003209340A1
(en)
*
|
2002-01-18 |
2003-09-02 |
Bristol-Myers Squibb Company |
Predictor sets for tyrosine kinase pathways
|
CA2480052A1
(en)
*
|
2002-04-01 |
2003-10-16 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
JP2005535572A
(ja)
|
2002-04-12 |
2005-11-24 |
メディミューン,インコーポレーテッド |
組換え抗インターロイキン−9抗体
|
CA2485548A1
(en)
|
2002-05-10 |
2004-02-19 |
Purdue Research Foundation |
Epha2 agonistic monoclonal antibodies and methods of use thereof
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
DK1534335T4
(da)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
Fcgammariib-specifikke antistoffer og fremgangsmåder til anvendelse deraf
|
CA2497628A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
US8071569B2
(en)
*
|
2002-09-20 |
2011-12-06 |
Mousa Shaker A |
Oxidized heparin fractions and their use in inhibiting angiogenesis
|
PT2891666T
(pt)
|
2002-10-16 |
2017-09-22 |
Purdue Pharma Lp |
Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização
|
MXPA05007615A
(es)
*
|
2003-01-21 |
2005-09-30 |
Bristol Myers Squibb Co |
Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
|
US7662783B2
(en)
*
|
2003-02-20 |
2010-02-16 |
New York University |
CLK-peptide and SLK-peptide
|
US7601694B2
(en)
*
|
2003-02-20 |
2009-10-13 |
New York University |
CLK-peptide and SLK-peptide
|
US7387998B2
(en)
*
|
2003-03-28 |
2008-06-17 |
New York University |
STQ peptides
|
EP2316487B1
(en)
|
2003-04-11 |
2014-06-11 |
MedImmune, LLC |
Recombinant IL-9 antibodies & uses thereof
|
MEP31408A
(en)
|
2003-07-18 |
2010-10-10 |
Abgenix Inc |
Specific binding agents to hepatocyte growth factor
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
WO2005042743A2
(en)
|
2003-08-18 |
2005-05-12 |
Medimmune, Inc. |
Humanization of antibodies
|
WO2005058961A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
WO2005079508A2
(en)
*
|
2004-02-17 |
2005-09-01 |
Cancervax Corporation |
Method and composition for angiogenesis inhibition
|
WO2005090406A2
(en)
|
2004-03-12 |
2005-09-29 |
Vasgene Therapeutics, Inc. |
Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
|
US7973139B2
(en)
*
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
EP2380872B1
(en)
*
|
2004-06-15 |
2014-04-23 |
Cellceutix Corporation |
Polycationic compounds and uses thereof
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US20070275874A1
(en)
*
|
2004-09-03 |
2007-11-29 |
Yale University |
Use of Leptin in Wound Healing
|
EP1812468A2
(en)
*
|
2004-09-15 |
2007-08-01 |
K.U.Leuven Research & Development |
Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2006034455A2
(en)
|
2004-09-23 |
2006-03-30 |
Vasgene Therapeutics, Inc. |
Polipeptide compounds for inhibiting angiogenesis and tumor growth
|
US7935790B2
(en)
*
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
US20060121042A1
(en)
|
2004-10-27 |
2006-06-08 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
CA2588273A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Bioquanta Corp. |
Pf4 pharmacophores and their uses
|
US7807789B2
(en)
*
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
US20060240002A1
(en)
*
|
2005-03-11 |
2006-10-26 |
Brooks Peter C |
Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
|
US20060216237A1
(en)
*
|
2005-03-11 |
2006-09-28 |
Brooks Peter C |
Inhibition of angiogenesis and tumor development by IGFBP-4
|
US20060216236A1
(en)
*
|
2005-03-11 |
2006-09-28 |
Brooks Peter C |
Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP2301969B1
(en)
|
2005-05-06 |
2015-12-23 |
ZymoGenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
WO2007008604A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
US20070048325A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Dennis Van Epps |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP1934867A2
(en)
*
|
2005-08-31 |
2008-06-25 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
CA2628238A1
(en)
|
2005-11-07 |
2007-05-18 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
US20080108664A1
(en)
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
AU2007207764B2
(en)
|
2006-01-12 |
2012-06-07 |
Alexion Pharmaceuticals, Inc. |
Antibodies to OX-2/CD200 and uses thereof
|
CA2641713C
(en)
|
2006-02-10 |
2011-11-22 |
Amgen Inc. |
Hydrate forms of amg706
|
WO2007127335A2
(en)
*
|
2006-04-27 |
2007-11-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
|
AU2007244683A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
JP5764290B2
(ja)
|
2006-06-26 |
2015-08-19 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体およびその使用法
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
US7939636B2
(en)
*
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
NZ575163A
(en)
|
2006-08-28 |
2011-12-22 |
Jolla Inst Allergy Immunolog |
Antagonistic human light-specific human monoclonal antibodies
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP2759549B1
(en)
|
2006-09-01 |
2015-08-19 |
ZymoGenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
US20100143254A1
(en)
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
CN101835485B
(zh)
|
2007-02-01 |
2016-10-26 |
阿塞勒隆制药公司 |
活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途
|
US8314087B2
(en)
|
2007-02-16 |
2012-11-20 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and methods of use
|
EP1972639A3
(en)
|
2007-03-07 |
2008-12-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
US20090068684A1
(en)
*
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
MX2009010389A
(es)
|
2007-03-30 |
2010-01-20 |
Medimmune Llc |
Formulacion de anticuerpos.
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
EP1983002A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
AU2008246442B2
(en)
|
2007-05-04 |
2014-07-03 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
BRPI0811526A2
(pt)
|
2007-05-14 |
2017-05-16 |
Biowa Inc |
uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa
|
TWI595005B
(zh)
|
2007-08-21 |
2017-08-11 |
安健股份有限公司 |
人類c-fms抗原結合蛋白質
|
CN101861161B
(zh)
|
2007-09-18 |
2017-04-19 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
WO2009071696A2
(en)
|
2007-12-07 |
2009-06-11 |
Zymogenetics, Inc. |
Humanized antibody molecules specific for il-31
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
WO2010015608A1
(en)
|
2008-08-05 |
2010-02-11 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
ES2548030T3
(es)
|
2009-06-01 |
2015-10-13 |
Medimmune, Llc |
Moléculas con semividas prolongadas y usos de las mismas
|
WO2011005481A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
DK2769737T3
(da)
|
2009-07-20 |
2017-07-24 |
Bristol Myers Squibb Co |
Kombination af et anti-ctla4-antistof med etoposid til synergistisk behandling af proliferative sygdomme
|
US9133500B2
(en)
|
2009-08-10 |
2015-09-15 |
MorphoSys A6 |
Screening strategies for the identification of binders
|
WO2011020024A2
(en)
|
2009-08-13 |
2011-02-17 |
The Johns Hopkins University |
Methods of modulating immune function
|
IN2012DN01328A
(da)
*
|
2009-08-13 |
2015-06-05 |
Crucell Holland Bv |
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
CN103038258B
(zh)
|
2010-05-06 |
2017-02-15 |
诺华股份有限公司 |
用于治疗低密度脂蛋白相关蛋白质6(lrp6)的抗体的组合物及使用方法
|
AU2011249782B2
(en)
|
2010-05-06 |
2014-10-02 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
|
EA037095B1
(ru)
|
2010-07-09 |
2021-02-05 |
Биовератив Терапьютикс Инк. |
Способ лечения гемофилии в и эпизодов кровотечения
|
CN103097412B
(zh)
|
2010-07-09 |
2016-08-10 |
克鲁塞尔荷兰公司 |
抗人呼吸道合胞病毒(rsv)抗体以及使用方法
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
BR112013004012B1
(pt)
|
2010-08-20 |
2021-03-23 |
Novartis Ag |
Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
|
EP2608807A1
(en)
|
2010-08-27 |
2013-07-03 |
Stem Centrx, Inc. |
Notum protein modulators and methods of use
|
NZ608814A
(en)
|
2010-09-03 |
2015-06-26 |
Stem Centrx Inc |
Novel modulators and methods of use
|
RS59589B1
(sr)
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
SG10201601792UA
(en)
|
2010-12-08 |
2016-04-28 |
Stemcentrx Inc |
Novel modulators and methods of use
|
EP2668210B1
(en)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
CA2830516C
(en)
|
2011-03-23 |
2017-01-24 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
EP2758422A1
(en)
|
2011-09-23 |
2014-07-30 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Modified albumin-binding domains and uses thereof to improve pharmacokinetics
|
EP2773665A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
EP2773373B1
(en)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
US9220774B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of treating cancer by administering anti-GPR49 antibodies
|
EP2773667A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
JP6326371B2
(ja)
|
2011-11-04 |
2018-05-16 |
ザイムワークス,インコーポレイテッド |
Fcドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
|
CN104039830A
(zh)
|
2011-11-04 |
2014-09-10 |
诺华股份有限公司 |
低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
|
WO2013081993A1
(en)
|
2011-12-02 |
2013-06-06 |
Eli Lilly And Company |
Anti-glucagon antibodies and uses thereof
|
SG11201402739YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
EP3590538A1
(en)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
EP3330288A1
(en)
|
2011-12-21 |
2018-06-06 |
Novartis AG |
Compositions and methods for antibodies targeting factor p
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
PE20150091A1
(es)
|
2012-02-24 |
2015-02-16 |
Stem Centrx Inc |
Anticuerpos anti-sez6 y metodos de empleo
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CA2868883C
(en)
|
2012-03-30 |
2022-10-04 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
JP6351572B2
(ja)
|
2012-05-10 |
2018-07-04 |
ザイムワークス,インコーポレイテッド |
Fcドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
|
TWI702955B
(zh)
|
2012-05-15 |
2020-09-01 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
SG11201500489YA
(en)
|
2012-07-25 |
2015-02-27 |
Kolltan Pharmaceuticals Inc |
Anti-kit antibodies and uses thereof
|
AU2013329311A1
(en)
|
2012-10-09 |
2015-04-30 |
Igenica Biotherapeutics, Inc. |
Anti-C16orf54 antibodies and methods of use thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
AP2015008365A0
(en)
|
2012-12-05 |
2015-04-30 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
CA2891686A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
HUE043851T2
(hu)
|
2013-02-22 |
2019-09-30 |
Abbvie Stemcentrx Llc |
Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
|
ES2644022T3
(es)
|
2013-03-14 |
2017-11-27 |
Bristol-Myers Squibb Company |
Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
TWI683666B
(zh)
|
2013-03-15 |
2020-02-01 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
KR102553717B1
(ko)
|
2013-08-26 |
2023-07-11 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
JP2016538318A
(ja)
|
2013-08-28 |
2016-12-08 |
ステムセントリックス, インコーポレイテッド |
新規sez6モジュレーターおよび使用方法
|
EP3892294A1
(en)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Site-specific antibody conjugation methods and compositions
|
AU2014342610A1
(en)
|
2013-11-04 |
2016-06-02 |
Abbvie Stemcentrx Llc |
Anti-EFNA4 antibody-drug conjugates
|
EP3097122B9
(en)
|
2014-01-24 |
2020-11-11 |
NGM Biopharmaceuticals, Inc. |
Antibodies binding beta klotho domain 2 and methods of use thereof
|
US10308721B2
(en)
|
2014-02-21 |
2019-06-04 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
SG10201810150UA
(en)
|
2014-03-17 |
2018-12-28 |
Adverum Biotechnologies Inc |
Compositions and methods for enhanced gene expression in cone cells
|
MX2016012873A
(es)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
|
KR102246800B1
(ko)
|
2014-05-13 |
2021-04-30 |
바이오아트라, 인코퍼레이티드 |
조건부 활성 생체 단백질
|
JP6832709B2
(ja)
|
2014-05-16 |
2021-02-24 |
メディミューン,エルエルシー |
新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
|
JP6626461B2
(ja)
|
2014-06-04 |
2019-12-25 |
バイオエヌテック リサーチ アンド デベロップメント, インコーポレイテッド |
ガングリオシドgd2に対するヒトモノクローナル抗体
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
WO2016020880A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
TW201613977A
(en)
|
2014-08-07 |
2016-04-16 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
AU2015311911B2
(en)
|
2014-09-03 |
2019-01-24 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
WO2016094837A2
(en)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
CN107405507B
(zh)
|
2015-03-02 |
2022-05-03 |
阿德夫拉姆生物技术股份有限公司 |
用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
|
BR112017015880A2
(pt)
|
2015-03-03 |
2018-07-31 |
Kymab Ltd |
anticorpos, usos e métodos
|
AU2016258115A1
(en)
|
2015-05-06 |
2017-11-23 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
|
EA201792561A1
(ru)
|
2015-06-05 |
2018-04-30 |
Новартис Аг |
Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
KR20180035852A
(ko)
|
2015-08-03 |
2018-04-06 |
노파르티스 아게 |
Fgf21-연관 장애를 치료하는 방법
|
PE20181368A1
(es)
|
2015-09-09 |
2018-08-27 |
Novartis Ag |
Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas
|
MY186352A
(en)
|
2015-09-09 |
2021-07-15 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
KR20180054824A
(ko)
|
2015-09-29 |
2018-05-24 |
셀진 코포레이션 |
Pd-1 결합 단백질 및 이의 사용 방법
|
WO2017078839A1
(en)
|
2015-11-02 |
2017-05-11 |
Bioatla, Llc |
Conditionally active polypeptides
|
RU2018124307A
(ru)
|
2015-12-04 |
2020-01-14 |
Новартис Аг |
Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
|
KR20180089510A
(ko)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
CD32b를 표적화하는 항체 및 그의 사용 방법
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
US20210198368A1
(en)
|
2016-01-21 |
2021-07-01 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子15に対する抗体およびそれらの使用
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
EP3471759A1
(en)
|
2016-06-15 |
2019-04-24 |
Novartis AG |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
EP3481866B1
(en)
|
2016-07-06 |
2024-07-24 |
Bristol-Myers Squibb Company |
Combination of tim-4 antagonist and pd-1 antagonist and methods of use
|
BR112019004733A2
(pt)
|
2016-09-19 |
2019-05-28 |
Celgene Corp |
métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
EP3515495A4
(en)
|
2016-09-26 |
2020-08-26 |
Ensemble Group Holdings |
METHOD OF EVALUATION AND TREATMENT OF CANCER IN HUMANS WITH DYSREGULATED LYMPHATIC SYSTEMS
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
HUE056777T2
(hu)
|
2016-12-22 |
2022-03-28 |
Amgen Inc |
Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
|
CN118320078A
(zh)
|
2016-12-23 |
2024-07-12 |
诺华股份有限公司 |
采用抗因子XI/XIa抗体治疗的方法
|
IL308980A
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Antibodies against factor XI and methods of their use
|
WO2018146594A1
(en)
|
2017-02-08 |
2018-08-16 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
AU2018274216A1
(en)
|
2017-05-24 |
2019-12-12 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
MA50077A
(fr)
|
2017-09-08 |
2020-07-15 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
EP3694889A1
(en)
|
2017-10-13 |
2020-08-19 |
Boehringer Ingelheim International GmbH |
Human antibodies to thomsen-nouvelle (tn) antigen
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
US11492409B2
(en)
|
2018-06-01 |
2022-11-08 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
CA3106418A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MX2021007156A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Inhibidores de kif18a.
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
JP2022522778A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロシクリル化合物及びその使用
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
WO2020236792A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
US11236091B2
(en)
|
2019-05-21 |
2022-02-01 |
Amgen Inc. |
Solid state forms
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114269731A
(zh)
|
2019-08-02 |
2022-04-01 |
美国安进公司 |
Kif18a抑制剂
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
JP2022553859A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
WO2021091967A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
AU2021206217A1
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines, Inc. |
SHP2 inhibitor dosing and methods of treating cancer
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
EP4143224A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Immunoglobulin variants
|
WO2021220215A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Engineered immunoglobulins
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
JP2024502832A
(ja)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ, インコーポレイテッド |
高親和性及び/または特異性を有する結合剤分子ならびにその製造及び使用方法
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
KR20240130138A
(ko)
|
2022-01-07 |
2024-08-28 |
존슨 앤드 존슨 엔터프라이즈 이노베이션 인코포레이티드 |
Il-1 베타 결합 단백질의 재료 및 방법
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
AR129136A1
(es)
|
2022-04-26 |
2024-07-17 |
Novartis Ag |
Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
CN114805536B
(zh)
*
|
2022-06-24 |
2022-09-02 |
北京百臻生物技术有限公司 |
一种人血小板因子4蛋白突变体及其应用
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
CN116375859A
(zh)
*
|
2023-06-05 |
2023-07-04 |
北京大学第一医院 |
一种抗vWF/PF4蛋白的单克隆抗体及其应用
|